DK1154786T3 - Sammensætninger til modulering af mucus-sekretionen - Google Patents

Sammensætninger til modulering af mucus-sekretionen

Info

Publication number
DK1154786T3
DK1154786T3 DK00912034T DK00912034T DK1154786T3 DK 1154786 T3 DK1154786 T3 DK 1154786T3 DK 00912034 T DK00912034 T DK 00912034T DK 00912034 T DK00912034 T DK 00912034T DK 1154786 T3 DK1154786 T3 DK 1154786T3
Authority
DK
Denmark
Prior art keywords
mucus secretion
compositions
modulating
modulating mucus
secretion
Prior art date
Application number
DK00912034T
Other languages
English (en)
Inventor
Linda D Martin
Yuehua Li
Kenneth B Adler
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Application granted granted Critical
Publication of DK1154786T3 publication Critical patent/DK1154786T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00912034T 1999-02-24 2000-02-24 Sammensætninger til modulering af mucus-sekretionen DK1154786T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25615499A 1999-02-24 1999-02-24
PCT/US2000/005050 WO2000050062A2 (en) 1999-02-24 2000-02-24 Methods and compositions for altering mucus secretion

Publications (1)

Publication Number Publication Date
DK1154786T3 true DK1154786T3 (da) 2005-02-14

Family

ID=22971264

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00912034T DK1154786T3 (da) 1999-02-24 2000-02-24 Sammensætninger til modulering af mucus-sekretionen
DK04024019.4T DK1538162T3 (da) 1999-02-24 2000-02-24 Sammensætninger til ændring af slimsekretion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04024019.4T DK1538162T3 (da) 1999-02-24 2000-02-24 Sammensætninger til ændring af slimsekretion

Country Status (10)

Country Link
EP (2) EP1538162B1 (da)
JP (2) JP5620037B2 (da)
AT (2) ATE279206T1 (da)
AU (1) AU766800B2 (da)
CA (1) CA2366951A1 (da)
DE (1) DE60014856T2 (da)
DK (2) DK1154786T3 (da)
ES (2) ES2391225T3 (da)
PT (1) PT1154786E (da)
WO (1) WO2000050062A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
PT1411967E (pt) * 2001-06-26 2011-09-30 Univ North Carolina State Péptido bloqueador que atua sobre a secreção de células inflamatórias
US6943021B2 (en) * 2002-06-07 2005-09-13 Mattek Corporation Three dimensional vaginal tissue model containing immune cells
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
NZ577196A (en) 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
WO2006086681A2 (en) 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
JP2017504320A (ja) * 2013-12-20 2017-02-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 低剪断マイクロ流体デバイスならびにその使用および製造の方法
WO2016011301A1 (en) * 2014-07-17 2016-01-21 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for novel anticoagulants in the coagulation pathway
JP2022537318A (ja) 2019-06-17 2022-08-25 バイオマルク ファーマシューティカルズ リミテッド ぶどう膜炎の処置におけるペプチド及びその使用の方法
WO2022020985A1 (zh) * 2020-07-27 2022-02-03 上海市公共卫生临床中心 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用
EP4475866A4 (en) * 2022-02-07 2026-02-25 Park Strategic Ventures Llc Peptides and their methods of use in the treatment of eye disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
CA2093125C (en) * 1990-10-02 2003-12-16 Warner-Lambert Company Angiotensin ii antagonists
EP0593580A4 (en) * 1991-06-20 1995-12-06 Us Health Sequences characteristic of human gene transcription product
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) * 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
JPH10502333A (ja) * 1994-04-07 1998-03-03 プロティーンニックス カンパニー バソアクティブ・インテスティナル・ポリペプチド

Also Published As

Publication number Publication date
CA2366951A1 (en) 2000-08-31
EP1154786A2 (en) 2001-11-21
JP2015007065A (ja) 2015-01-15
ATE279206T1 (de) 2004-10-15
JP5620037B2 (ja) 2014-11-05
WO2000050062A3 (en) 2000-12-21
AU3383300A (en) 2000-09-14
DE60014856D1 (de) 2004-11-18
ES2391225T3 (es) 2012-11-22
AU766800B2 (en) 2003-10-23
EP1538162B1 (en) 2012-04-11
DE60014856T2 (de) 2006-02-02
ATE553121T1 (de) 2012-04-15
PT1154786E (pt) 2005-02-28
JP2002538783A (ja) 2002-11-19
WO2000050062A2 (en) 2000-08-31
EP1538162A3 (en) 2005-06-15
DK1538162T3 (da) 2012-07-23
EP1538162A2 (en) 2005-06-08
HK1041654A1 (en) 2002-07-19
ES2230078T3 (es) 2005-05-01
EP1154786B1 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
DK1154786T3 (da) Sammensætninger til modulering af mucus-sekretionen
MY129356A (en) Electrospun pharmaceutical compositions
ATE312843T1 (de) Neues cyclosporin mit verbesserter wirkung
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
DE60019116D1 (de) Neue omeprazole und (s)-omeprazole zusammensetzung
HRP20010119B1 (hr) Sprječavanje stvaranja sluzi u dišnim putevima primjenom antagonista egf-r
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
DE69831504T2 (de) Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole)
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DK1003486T3 (da) Farmaceutisk præparat indeholdende et bruse-syre-basepar
HUP0003349A3 (en) Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE178484T1 (de) Protein enthaltende stabilisierte formulierung und dosierungskit
BR0009678A (pt) Compostos, composição farmacêutica, e, uso de compostos
DE60019334D1 (de) Antivirale arznei
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
DE60135261D1 (de) Arzneimittel, welches ein Peptid kleiner oder mittlerer Grösse enthält
ES2194237T3 (es) Preparaciones cosmeticas.
NZ516413A (en) Extended release dose regimens for lasofoxifene ((-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol)
GB0028130D0 (en) Polypeptide and uses thereof
DE69938130D1 (de) Neue peptide
DE69727583D1 (de) Vermeidung von gastrointestinaler schädigung
TW200503748A (en) Biologically active peptide comprising tyrosyl-seryl-valine (YSV)
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.